Related Experiment Video
Updated: Jul 5, 2026
06:39
Intracoronary Acetylcholine Provocation Testing for Assessment of Coronary Vasomotor Disorders
Published on: August 18, 2016
PPARgamma agonists and coronary atherosclerosis
Melanie S Sulistio1, Adrienne Zion, Nandish Thukral
1University of Texas Health Science Center at San Antonio, Department of Cardiology, 7300 Medical Drive, San Antonio, TX 78229, USA. sulistio@uthscsa.edu
Current Atherosclerosis Reports
|April 18, 2008
Summary
Type 2 diabetes mellitus (T2DM) and cardiovascular disease share insulin resistance as a key link. Thiazolidinediones (TZDs) offer T2DM treatment benefits, but their cardiovascular risks are under investigation.
Area of Science:
- Endocrinology
- Cardiology
- Pharmacology
Background:
- Type 2 diabetes mellitus (T2DM) prevalence is epidemic, with cardiovascular disease as a leading cause of death.
- Insulin resistance links T2DM to macrovascular complications and atherosclerosis.
- Thiazolidinediones (TZDs), PPAR-gamma agonists, treat T2DM and affect lipid profiles.
Purpose of the Study:
- To review the link between insulin resistance and atherosclerosis.
- To discuss major Thiazolidinediones (TZD) clinical trials.
- To address clinical implications and controversies surrounding TZD use and myocardial infarction risk.
Main Methods:
- Literature review of basic science on insulin resistance and atherosclerosis.
- Analysis of recent major Thiazolidinediones (TZD) clinical trials.
- Examination of clinical outcomes and media reports on TZD-associated myocardial infarction.
Main Results:
- Insulin resistance detrimentally affects the macrovasculature, contributing to atherosclerosis.
- Thiazolidinediones (TZDs) demonstrate benefits in T2DM treatment and lipid modification.
- Recent studies and media reports raise concerns about potential increased myocardial infarction risk with TZD use.
Conclusions:
- Understanding the link between insulin resistance and atherosclerosis is crucial for managing T2DM and cardiovascular risk.
- Thiazolidinediones (TZDs) present a complex risk-benefit profile in T2DM management.
- Further research and careful patient selection are necessary to clarify the cardiovascular safety of Thiazolidinediones (TZDs).
Related Concept Videos
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
01:16Antianginal Drugs: Nitrates and β-Blockers
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
01:22Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
01:27Coronary Artery Disease V: Interprofessional Care
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...